CI — Cigna Corporation

Cigna Group Q4 2025 Earnings Call Summary

1. Key Financial Results and Metrics

• Full-Year Adjusted Revenue: $275 billion, up 11% year-over-year.
• Adjusted Earnings Per Share (EPS): $29.84, a 9% increase.
• After-Tax Special Item Charges: $483 million or $1.82 per share.
• Fourth Quarter Revenue: $63.1 billion.
• Fourth Quarter Adjusted Earnings: $2.2 billion for EverNorth; $734 million for Cigna Healthcare.
• Cash Flow from Operations: $9.6 billion for 2025.

2. Strategic Updates and Business Highlights

• Portfolio Shaping: Continued focus on specialty capabilities, including an investment in Shields Health Solutions.
• Pharmacy Benefit Model: Transition to a rebate-free model aimed at enhancing transparency and reducing costs for consumers.
• FTC Settlement: A comprehensive resolution with the FTC expected to provide $7 billion in out-of-pocket cost relief over ten years for customers.
• Customer Experience: Improved customer net promoter scores across major business segments.
• Innovations: Launch of Clarity, a new offering designed to enhance cost transparency and simplify healthcare access.

3. Forward Guidance and Outlook

• 2026 Adjusted EPS Guidance: At least $30.25, indicating continued growth.
• 2026 Adjusted Revenue Projection: Approximately $280 billion.
• EverNorth Earnings Expectation: At least $6.9 billion for 2026, with significant investment in the rebate-free model.
• Cigna Healthcare Earnings Expectation: At least $4.5 billion for 2026, with a medical care ratio (MCR) projected between 83.7% to 84.7%.

4. Bad News, Challenges, or Points of Concern

• Higher Medical Costs: Notable increase in medical costs contributing to a higher MCR, which may affect profitability.
• Market Dynamics: Continued elevated cost trends in healthcare, driven by aging populations and chronic conditions.
• Membership Outlook: Anticipated flat membership at 18.1 million, with declines in individual exchange customers.
• Investment Costs: Expected investment-related costs in 2026 for the new pharmacy benefit model may pressure earnings in the short term.

5. Notable Q&A Insights

• PBM Model Transition: Management confirmed that the new pharmacy benefit model aligns with regulatory expectations and will not adversely impact earnings in 2027.
• Client Adoption Rates: The entire Cigna Healthcare fully insured book will adopt the new model by 2027, with at least 50% of EverNorth clients expected to transition by 2028.
• Formulary Changes: Future formulary adjustments will be based on clinical efficacy and effectiveness, not directly tied to the new pricing model.
• Cash Flow Expectations: A projected decline in cash flow to $9 billion for 2026, primarily due to lower contributions from the pharmacy benefit services segment.

Overall, Cigna Group demonstrated strong financial performance in 2025, with strategic initiatives aimed at enhancing customer value and addressing healthcare affordability, despite facing challenges related to rising medical costs and membership dynamics.